Expand all sections

Abrocitinib

Cibinqo

Extended indication

Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to

Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Abrocitinib
Domain

Chronic immune diseases
Reason of inclusion

Indication extension
Main indication

Skin diseases
Extended indication

Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis
Proprietary name

Cibinqo
Manufacturer

Pfizer
Mechanism of action

JAK tyrosine kinase inhibitor
Route of administration

Oral
Therapeutical formulation

Tablet
Budgetting framework

Extramural (GVS)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
Submission date

June 2023
Expected Registration

April 2024
Orphan drug

No
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.